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Abstract: Objectives: Neuropathic pain (NeP) is a prevalent, disabling, multi-dimensional
condition with significant morbidity; however there appears to be a variable approach in
the use of outcome measures in NeP trials. A search of systematic reviews of
interventional randomized controlled trials for NeP was undertaken to investigate the
range and types of outcome measures employed to determine treatment effects.
Methods: Keywords and MESH searches were conducted in five electronic databases
from inception to 31st January 2012. Full text English language reviews based on
various acute and chronic NeP conditions were included. Two independent reviewers
screened papers for inclusion, extracted data, and assessed the quality of reviews.
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
guidelines were used to critically appraise the reviews.
Results: A total of 46 studies were identified: the majority of reviews (n=28/46, 61%)
scored well on the PRISMA (PRISMA scores of 20-27/27). Change in levels or intensity
of pain were used by the majority of studies as the primary outcome measure in
intervention studies (n=40/46 studies, 87%). Few studies employed a functional
outcome measure (FOM) as either a primary or secondary outcome measure (n=7/46,
15% of studies).
Discussion: These results demonstrate that measures of pain are predominantly used
in trials of NeP conditions and highlight the scant usage of FOMs. The lack of
standardization for the diagnostic criteria in NeP trials is also an issue which needs to
be considered for future research and guideline development.
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Reviewer 1   
COMMENT EXPLAINATION MODIFICATIONS  
(Highlighted text) 
It seems you missed my point. 
You included a review of disease modifying 
therapies (not symptomatic pain therapies) 
1. You included a review and not the original 
articles 
2. The review was of a disease modifying therapy - 
pain was not the primary efficacy endpoint in most 
or all of the trials in the review 
3. If you feel that these interventions (i.e., disease 
modifying trials) are under your purview, there are 
dozens of articles that you have left out 
We note the reviewer’s concern here. Since this is a systematic 
review of systematic reviews, there is a potential that many 
other similar studies (based on disease modifying therapies) 
might have left out, so we have agreed to exclude Chalk C et al. 
systematic reviews from the manuscript. 
Necessary modifications have been made 
in the sections of Abstract, Methodology 
(inclusion criteria), Results, Discussion, 
Figure, Tables 2, 4, 5, and Reference list. 
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INTRODUCTION 
Defining ‘Neuropathic Pain- NeP’ has proved a challenge to health care,1 due primarily to 
the lack of a ‘gold standard’ test to confirm the presence of this pain state2 and resultant 
variability in diagnostic classifications among both clinicians and researchers. The original 
IASP (International Association for the Study of Pain) definition of NeP, “pain initiated or 
caused by a primary lesion or dysfunction in the nervous system”3 has been proposed to be 
replaced by NeuPSIG (IASP Special Interest Group on NeP) with the wording of “pain arising 
as a direct consequence of a lesion or disease affecting the somatosensory system”.2 The 
rationale for this new definition is that ‘dysfunction’, which in itself is a very vague term, is 
not able to differentiate between NeP and other pain states such as inflammatory pain4 and 
musculoskeletal pain.5 
For chronic pain conditions, the Initiative on Methods, Measurement and Pain 
Assessment in Clinical Trials (IMMPACT) has recommended use of six core outcome domains 
in clinical trials: pain; physical functioning; emotional functioning; participant rating of 
improvement and satisfaction with treatment; symptoms and adverse events; and 
participant disposition.6 Importantly, it has been found that due to the range and variability 
of outcome assessments employed in pain intervention studies, decisions on comparative 
effectiveness for available treatments remains problematic.6 Thus, to measure the efficacy 
and effectiveness in clinical trials of chronic pain, a set of core outcome measures for each 
domain has also been recommended.7 In addition, outcome measures are also 
recommended for use for specific chronic pain conditions such as osteoarthritis,8 low back 
pain,9, 10 and NeP.5, 11 
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Both the European Federation of Neurological Societies (EFNS)5 and the Neuropathic Pain 
Special Interest Group (NeuPSIG)11 have evaluated the existing evidence for methods of NeP 
assessment, and formulated guidelines for assessing and managing patients. For NeP 
intensity, usage of one-dimensional pain scales (e.g. Visual Analogue Scale and pain relief 
scales) were highly recommended over the use of non-specific multidimensional scales (e.g. 
McGill Pain Questionnaire).5 It has also been previously stated that rating of severity and 
unpleasantness of pain should be done separately.5, 12 Since these chronic conditions are 
multidimensional, both EFNS and NeuPSIG guidelines have recommended that, in 
conjunction to pain, quality of life (mood, sleep, anxiety and depression), as well as 
functional capacity (physical, cognitive, emotional and social), should also be assessed as 
secondary outcome measures. 5, 11 
Despite the extensive research base in NeP, and the availability of IMMPACT guidelines 
for chronic pain assessment and EFNS & NeuPSIG guidelines for NeP assessment, to our 
knowledge, outcomes used in NeP trials have not previously been investigated. Thus, the 
objective of this review was to systematically review systematic reviews of interventional 
RCTs for NeP to investigate the range and types of outcome measures used to determine 
treatment effect. 
METHOD 
Eligibility Criteria: Selection criteria for this review included systematic review designs of 
interventional RCTs in the symptomatic management of NeP conditions, as defined by the 
Clinical Resource Efficiency Support Team (CREST).13 Systematic reviews of both acute (less 
than 3 months duration) and chronic pain conditions (3 months duration or more)14 were 
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included. Narrative reviews or systematic reviews of non-RCTs were not included. 
Systematic reviews were restricted to those published in English. 
Information Sources: The following electronic databases were searched: Ovid Medline, 
CINAHL, The Cochrane central register of controlled trials, AMED, and Web of Science (WOS) 
(from database inception to 31 January 2012). The search strategy for Ovid Medline is 
detailed in Table 1; this search strategy was amended for other databases. Reference lists of 
included systematic reviews were not searched for further systematic reviews. 
Study Selection: Two reviewers (PM and LC), independently selected articles for potential 
eligibility at title and abstract stages. Full text articles of all potentially eligible abstracts 
were retrieved for application of the eligibility criteria. To determine the usability of 
Treede’s Guidelines for reporting NeP, all recently published (2008 onwards) systematic 
reviews were graded for the level of certainty for the presence of NeP2 independently by 
two reviewers (PM and LC). The grading system is detailed in Table 3. 
Data collection process and data items: The following data were collected and tabulated 
from each of the included systematic reviews: study reference, objectives, population, 
number of RCTs, intervention type, primary and secondary outcome measures, and results. 
Data extraction was carried out independently by two reviewers (PM and SW) using 
standardised forms, with consensus meetings and opinions from other reviewers (LC and 
PH) to resolve any disagreements. 
Risk of bias in individual reviews: The Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA)15 was independently used by two reviewers (PM and LC) to 
critically appraise the included reviews. The PRISMA has been used previously in other 
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systematic reviews of systematic reviews to critically appraise the quality of systematic 
reviews.16 Disagreements regarding inclusion of individual reviews and PRISMA scoring were 
resolved by discussion with reviewers (PH and DB). Reviewers were not blind to the journal 
affiliation or authors of the systematic reviews. Reviews were not excluded based on their 
PRISMA scores. 
Summary measures and data synthesis: Summary measures (mean difference (MD), 
weighted mean difference (WMD), Relative Risk Ratio (RRR), and Odds Ratio (OR)) were 
extracted for each outcome measure for each systematic review. Outcome measures used 
by each systematic review were grouped under the four recommended core chronic pain 
outcome domains: pain intensity, physical functioning, emotional functioning, and 
participant’s rating of overall improvement (assessed by the Patient Global Impression of 
Change scale, PGIC).7 Each domain was further sub-grouped based upon the summary 
measure used in the review, and the amount of change determined to be clinically relevant. 
RESULTS 
Study selection: Figure 1 summarises the study selection process. The search strategy 
resulted in 498 systematic reviews. After accounting for duplicate removal, title screening, 
abstract screening, and assessment of eligibility of full text articles, 61 systematic reviews 
were identified and retrieved for full text review. 
Common reasons for exclusion (n=15) were: eight reviews were based on non- RCTs 
(Furlan AD 2010, Kuwabara S 2008, Mailis-Gagnon A 2004, Mulvey MR 2010, Sekula RF 
2011, Simpson EL 2009, Sultan A 2008, and Watson CPN 2010); in five reviews, it was not 
clearly evident if patients had sensory involvement i.e. presence of pain (Allen D 2007, 
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Lancaster T 1995, Lockhart P 2009, Salinas RA 2010, and Teixeira LJ 2011); one review was 
excluded as it primarily included pain immediately after surgery (Toms L 2008); and one 
review was excluded as its focus was on disease modifying therapy not symptomatic pain 
therapy (Chalk C 2007). A total of 46 reviews remained after exclusion. 
Characteristics of included reviews: Details of all 46 eligible reviews are given in Table 2. 
Systematic reviews fulfilled all selection criteria and presented data on various underlying 
neuropathic conditions. 
Half, 57% (26/46) of systematic reviews included the following study populations: 
diabetic neuropathy (Chen W 2011,17 Hurley RW 2008,18 Ites KI 2011,19 Li H 2008,20 and 
Wong MC 200721), post herpetic neuralgia (Alper BS 2002,22 Hempenstall K 2005,23 Khaliq W 
2007,24 and Volmink J 199625), trigeminal neuralgia (Chole R 2007,26 Liu H 2010,27 Lopez BC 
2004,28 Yang M 2011,29 and Zakrzewska JJM 200830), or mixed NeP where all the covered 
conditions were well tabulated (Challapalli V 2005,31 Collins SL 2000,32 Eccles NK 2005,33 Gill 
D 2011,34 Goodyear-Smith F 2009,35 Häuser W 2011,36 McQuay HJ 1996,37 Moore RA 2009,38 
Moore RA 2011,39 Straube S 2008,40 Straube S 2010,41 and Wiffen PJ 201142). The systematic 
reviews based on mixed NeP populations were only included if a sub-group analysis of the 
underlying conditions was performed. 
Half of the remaining reviews (10/20 systematic reviews) were heterogeneous 
studies which included NeP of any aetiology (Ang CD 2008,43 Eisenberg E 2005,44 Eisenberg E 
2006,45 Eisenberg E 2006,46 Hollingshead J 2006,47 Lunn MP 2009,48 Mason L 2004,49 Moore 
RA 2005,50 Papaleontiou M 2010,51 Pittler MH 2008,52 Plested M 2010,53 Saarto T 2007,54 
Seidel S 2008,55 Tremont-Lukats IW 2005,56 White CM 2004,57 and Wiffen PJ 201158). There 
were four more reviews based on different conditions; Herpes Zoster (Cao H 201059), Painful 
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HIV-associated sensory neuropathy (Phillips TJC 201060), Entrapment Neuropathy (Caliandro 
P 201161 and Traumatic Spinal cord injury & Central NeP (Denkers MR 200262). 
Grading system for the presence of NeP: As Treede’s guidelines for reporting NeP were 
published in 2008, only recently published systematic reviews (after 2008) were graded for 
the presence of a clear statement criterion for the diagnosis of NeP.2 Of those 18 systematic 
reviews, we could identify only three reviews that met the criteria for definite (Chen W 
2011),17 probable (Moore RA 2009),38 or possible (Straube S 2010)41 NeP (Table 3). The rest 
of the reviews (15/18) did not provide sufficient or clear information for a NeP grade (Table 
2) to be given; we were therefore unable to classify those reviews under any designated 
NeP category. 
It has been observed that pain and other neurological symptoms due to peripheral 
or central nervous system disease or injury present in very similar ways, and this 
observation has led to a group designation for NeP.3 However the study population for the 
current systematic review covered within the included reviews all the common conditions 
associated with NeP (CREST, 2008).13 
Critical appraisal of included reviews: PRISMA scoring for the reviews are detailed in Table 4: 
28 out of 46 reviews achieved 20-27 points on the PRISMA, 14 scored 10-19 points, and four 
scored 9 points or less. Higher scores reflect higher internal validity of the systematic 
review.15 
Outcome measures 
Pain intensity: Changes in levels of pain intensity were used as the primary outcome 
measure in 40 out of 46 (87%) included systematic reviews (Table 2). A variety of pain scales 
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were used to measure intensity of pain (or its relief): Visual Analogue Scales (VAS), Verbal 
Rating Scales (VRS), Likert pain rating scales, the McGill Pain Questionnaire (MPQ), and 
Numerical Rating Scales (NRS). 
Physical functioning: Only 7 of the 46 (15%) included systematic reviews used a 
functional outcome measure as a primary or secondary outcome measure (Table 5). Ten 
different functional outcome measures were reported: Disability of the Arm, Shoulder and 
Hand questionnaire (DASH), Pain Disability Index, SF-36: physical functional component, 
daily activities measured by Video Relay Service (VRS), function interference measured by 
NRS, Western Ontario and McMaster Osteoarthritis Index (WOMAC): functional component, 
timed scored functional activity, functional reach test, timed meter to walk test (6m and 
15m walking speed), and interference with daily activities. 
Emotional functioning: 10/46 (i.e. 22%) systematic reviews assessed the emotional 
domain (Alper BS 2002, Caliandro P 2011, Chen W 2011, Lunn MP 2009, Papaleontiou M 
2010, Plested M 2010, Saarto T 2007, Seidel S 2008, White CM 2004, and Zakrzewska JJM 
2011). A range of measures were employed including scales for Quality of Life to evaluate 
depression, anxiety, and sleep, as part of the Health Survey (SF-36), (SF-12), and (SF-MCQ). 
Participant’s rating of overall improvement: The PGIC (Patient global impression of 
change) score was employed in 15/46 (33%) systematic reviews. The outcome was 
described by the number of patients with a “moderate”, “good” or “notable” improvement 
in their global response to treatment, or ‘at least moderate pain relief’ on a suitable 
categorical scale. 
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Subgrouping these reviews on the basis of summary measures adopted, 
demonstrated that 16/46 (35%) reviews used different forms of means to describe their 
treatment effects, including mean difference (MD), weighted mean difference (WMD) and 
standardized mean difference (SMD) at 95% of confidence interval levels (CIs). Relative Risk 
Ratio (RRR) and Odds Ratio (OR) were alternatively used to summarize the results; of the 33 
(26 and 7) systematic reviews which adopted RR or OR (respectively), 16 (14 and 2) reviews 
could be simply categorized into a dichotomous response of yes/no (i.e. 50% pain relief or 
not). Six systematic reviews described their results narratively, and 13 reviews also 
calculated the Number Needed to Treat (NNT). 
DISCUSSION 
 To our knowledge, this is the first systematic review of systematic reviews to 
investigate the usage of various pain and functional outcome measures in intervention trials 
of NeP conditions. The most interesting finding from the current review is that, although the 
majority of reviews scored highly on the PRISMA scale for internal validity, their focus in 
outcome measures were almost exclusively on pain intensity and not within other domains, 
recommended by IMMPACT,7 EFNS,5, 63-65 and NeuPSIG.11 Thus the findings from the current 
review were in contrast to other areas of pain management, where the aim is more 
commonly focussed on reduction of disability (e.g. inactivity) and enabling the person to 
achieve independence.66 Changes in level or intensity of pain was the most commonly used 
primary endpoint in NeP trials, with the majority of studies using either the VAS and/or the 
NRS pain measurement scales. This particular finding was in accordance with NeuPSIG 
guidelines in which VAS and NRS are highly recommended to assess intensity of pain and 
treatment effect.11 
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Despite our expectations for the usage of multidimensional pain scales, our results 
showed that one-dimensional measurements of pain were employed in 40/46 systematic 
reviews. An international, informally organized network aimed at improving Outcome 
Measurement in Rheumatology (OMERACT)8 recommended a core set of four domains 
(pain, physical function, patient global assessment and, for studies of at least one year: joint 
imaging) for outcome assessment, for future clinical trials of hip, knee and hand 
osteoarthritis. However a recent systematic review of chronic musculoskeletal pain 
outcomes,67 reported that over half (54%) of all pain outcome measures were based on uni-
dimensional measures such as VAS. In contrast, only 16% used multidimensional scales (e.g. 
MPQ) and 27% were multi-item scales that measured one dimension of pain (e.g. Neck 
Disability Index). The results of the current review demonstrate that the use of single item 
pain measures as the primary outcome measure is a common finding in the majority of 
chronic pain studies. There may be a number of reasons behind this finding, such as: the 
time required for assessment of other related domains (i.e. physical functioning, emotional 
impact, and global improvement), the patient burden associated with lengthy assessment 
procedures, or alternatively because research is focussed exclusively on pain intensity.67 
Additionally, for the recently published systematic reviews, we determined the level 
of certainty for the presence of NeP in accordance with Treede’s grading system.2 There was 
little consistency across recent reviews with respect to Treede’s guidelines for reporting 
NeP. Given that these criteria were published relatively recently (in 2008), the reviews 
published in or before 2008 were not evaluated for this property. However, even for these 
recently published systematic reviews, only a small number of studies followed the specified 
assessment and diagnostic criteria (Table 2). The majority of studies provided insufficient/ 
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unclear information about diagnosis and therefore according to this grading system, if a 
patient’s inclusion criterion does not fulfil the criteria for any of the three grading levels, 
then the study population is classified as unlikely to have a NeP condition. According to the 
IASP revised definition of NeP, it is a clinical description (and not a diagnosis) and there is a 
requirement for a lesion of the nervous system to be present, as a precursor to the pain 
state.14 However, others state that when no lesion can be demonstrated, the limits of 
current diagnostic technology do not always allow the possibility of NeP to be excluded.68 
Thus, it can be argued that there is a need to adopt and utilise validated criteria to define 
and grade NeP in research, as well as clinical practice. 
In order to determine clinically important differences in pain intensity, IMMPACT 
also proposed criteria to determine the patient’s evaluation of change. It has been 
suggested that a raw score change of approximately 1 point represents 15-20% change and 
signifies “less important change” in the pain scores. Changes of approximately 2 points i.e. 
30-36% change represent “much better”, “much improved”, or “meaningful” decrease in 
chronic pain. Finally, a decrease of ≥4 points denoting ≥50% change appears to represent a 
“very much improved”, “treatment success”, or “satisfactory improvement” of pain.7 
Because of the ease of administration, it has become a “gold standard” of outcome in 
chronic pain research.69 It is noteworthy that of the 40 reviews which employed pain as the 
primary outcome measure, only 23 followed the benchmarks provided by IMMPACT. Nine 
reviews selected ≥50% pain relief, as their primary outcome variable, while the other eight 
employed pain intensity reduction of ≥30- 50%. 
Pain has always been considered as a risk factor for, as well as a cause of disability.70 
It has also been shown that functional losses as well as mood disturbances are directly 
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related to an increased severity of peripheral NeP.71 Moreover, it is not only activities of 
daily living which are affected by this multi-disabling condition, but also the individual’s 
work potential, raising the economic burden both at individual and society level.72 Beyond 
this, the relationship between pain and functional limitation is varied and moderated by a 
number of factors, including psychological and social issues, and level of emotional 
support.69 Our results emphasise that multi-dimensional pain scales and measures of 
functional and emotional responses to pain are needed to better evaluate response to pain 
interventions, and also to allow better modelling of the factors which mediate and 
moderate such relationships. Multi-dimensional measures would also help to better 
evaluate how and why patients fail to respond to specific interventions and also potentially 
allow targeting of the key factors which are driving the patient's response to the 
intervention. 
Strengths and limitations: A number of strengths and limitations in this review should be 
acknowledged. 
Firstly, it is acknowledged that ‘Neuropathic Pain conditions’ is an umbrella term 
which covers a number of different conditions such as diabetic neuropathy, trigeminal 
neuralgia, and post herpetic neuralgia.13 For the search strategy, MESH terms/ key words 
indexed for neuropathy, neuralgia, and neurodynia were used to be as inclusive as possible. 
It is acknowledged that each health condition could have been separately searched and 
potentially this may have lessened the chances of missing systematic reviews. However, it is 
anticipated that these reviews would have been identified during the hand search process. 
Secondly, as this was a systematic review of systematic reviews, the emphasis was at 
the review level, rather than investigating individual RCTs. Each systematic review included 
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numerous RCTs, for example Hauser W (2011)36 reviewed 142 RCTs. Each systematic review 
detailed (usually in table format) each outcome measure used in the included RCTs. 
However, it is possible that not all outcome measures employed in the RCTs were fully 
described. Another possible reason for the usage of pain outcome measure in isolation may 
be that many included studies were apparently industry-driven, and therefore aimed at 
approval or registration, or new indication for a drug, rather than investigating the full 
profile of the effects. 
Thirdly, we rated the recently published reviews for the presence of NeP based on an 
internationally recommended grading criteria2 and found that the majority of reviews 
simply stated the condition, without clear or sufficient information regarding the likelihood 
of NeP being present. The remainder of the studies (published before 2008) were not 
assessed as these could not be expected to meet the same criteria. As the main aim of this 
systematic review was to investigate the range and type of outcome measures used in 
(RCTs) of NeP, it can be argued that the presence/ absence of an NeP grading system does 
not affect the quality or types of outcome measures employed. Thus systematic reviews 
were not excluded based on these criteria. 
Lastly, internationally recommended systematic review reporting guidelines 
(PRISMA) were followed for scoring the internal validity or methodological reporting of 
included reviews. Other methodological quality checklists of systematic reviews are also 
available including: Critical Appraisal Skills Program of systematic reviews (CASP),73 
Aggressive Research Intelligence Facility (ARIF),74 and Assessment of Multiple Systematic 
Reviews (AMSTAR).16 However instances of poor reporting of key information published in 
systematic reviews has been identified as an issue, which diminishes their value to clinicians 
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and researchers.15 As the PRISMA checklist has already been used to check out the 
methodological quality of the Cochrane review,75 to report the methodological quality, its 
use was preferred. 
Conclusion: We have presented extensive data which demonstrates that measures of pain 
are predominantly used in trials of NeP conditions and highlight the scant usage of physical 
FOMs. Since NeP is a multi-disabling condition with significant associated morbidity, usage 
of physical and emotional functional measures along with severity of pain as core outcomes 
is a key recommendation for future research in NeP intervention studies. 
Our analysis also showed that in recently published reviews, there is a lack of 
standardization of diagnostic criteria in NeP trials. Since appropriate diagnosis followed by 
the earliest appropriate management remains the primary target to minimise the risks of 
comorbidities and disabilities, this issue needs to be considered for future research and 
guidelines development. 
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FIGURE LEGEND 
Figure 1. Flow diagram summarising systematic search and study selection process 
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2.3 Table 1. Search Strategy 
Step Database search Results 
1 (neuropathic pain OR neuropathy OR neurodynia OR nerve pain OR 
neuralgia).mp. 
61826 
2 (activit* daily living OR funct* outcome OR funct* activit* OR funct* 
abilit* OR measur* OR scale OR parameter*).mp. 
1045383 
3 (systematic review OR systematic reviews).mp. 24973 
4 systematic review.m_titl. 16352 
5 (RCT OR randomised control trial OR randomized control trial).mp. 7569 
6 1 AND 2 AND 4 AND 5 29 
7 limit 6 to (English language and humans) 29 
8 remove duplicates from 7 27 
[mp = protocol supplementary concept, rare disease supplementary concept, title, original 
title, abstract, name of substance word, subject heading word, unique identifier] 
 
Table
1 
 
Table 2. Summary characteristics of included reviews 
Study reference Population (Treede’s Definition of NeP) No. 
of 
RCT's 
Outcome Measures Statistical Approach 
used by included 
studies 
Level of 
Change used by 
included 
studies 
Diabetic Neuropathy 
Chen W et al. 2011 Diabetic peripheral neuropathy (DEFINITE 
NeP) 
39 Primary outcome: Improvement of 30% in VAS or total 
symptom score, Global symptom improvement and 
changes in nerve conduction velocity. 
Secondary outcomes: Quality of life by SF-36 scales, 
Change in or absolute values of motor or sensory nerve 
conduction velocity, Adverse events. 
MD, WMD and RR 
with 95% CIs 
NA 
Hurley RW et al. 
2008 
Diabetic peripheral neuropathy (NA)  3 Pain score (with and without 50% reduction), PGIC 
rating at end point and adverse events. 
RR and WMD with 
95% CIs 
50% 
Ites KI et al. 2011 Diabetic peripheral neuropathy (UNCLEAR) 6 Measure of balance (question about balance, 
perception of falls risk and number of falls, Tinnetti 
Balance Assessment, Sway parameters, tendem stance, 
single leg stance, functional reach, ABC scale, failure 
rate during weight transfer task to unipedal stance with 
a tilting support surface). 
Effect size with 95% 
CIs and NNT 
NA 
Table
2 
 
Li H 2008 Diabetic peripheral neuropathy (NA)  10 Sensory impairment level, hot-cold temperature 
discrimination, current perception threshold, and pain 
levels using VAS. 
 Narrative synthesis NA 
Wong MC et al. 
2007 
Painful diabetic neuropathy (NA) 25 Primary: 50% reduction in pain and ‘moderate’, ‘good’, 
or ‘notable’ improvement in PGIC. 
Secondary: 30% reduction in pain and the number of 
patients who withdrew as a result of side effects. 
OR with 95% CI using 
a random effect 
model 
30-50% 
Diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, post stroke pain, Phantom limb pain, Fibromyalgia, CRPS and GB syndrome 
Challapalli V et al. 
2005 
Painful peripheral neuropathy, Plexopathy or 
radiculopathy, CRPS type I and II, Central 
pain from cerebrovascular lesions or 
tumours, Spinal cord injuries, Multiple 
sclerosis and other demyelinating diseases, 
Trigeminal neuralgia, Post-amputation pain, 
Fibromyalgia (NA) 
30 Intensity of spontaneous pain or its relief measured by 
any validated measurement tool and Adverse effects 
with enough intensity to cause study withdrawal or to 
decrease the dose of the drug. 
WMD and OR in a 
random effects model 
NA 
Collins SL et al. 
2000 
Diabetic neuropathy, post herpetic neuralgia 
(NA) 
19 Point global scale of pain relief or effectiveness or 
improvement and 50% or more reduction on VAS of 
pain intensity. 
RR and RB with 95% 
CI using fixed effect 
model 
≥50% 
3 
 
Eccles NK 2005 Acute pain induced by heat, foot pain from 
plantar fasciitis, postsurgical foot pain, 
chronic shoulder and neck pain, post-polio 
pain, low back pain, postsurgical wound pain, 
intractable neuropathic pain, chronic knee, 
and back pain, fibromyalgic pain, rheumatoid 
arthritic knee pain, osteoarthritic knee pain, 
chronic headache, wrist pain, carpal tunnel 
syndrome, chronic pelvic pain and monthly 
dysmenorrhea (NA)  
21 Level of pain was assessed using the McGill Pain and 
VAS, VRS, 11 point NRS, WOMAC, 15 m walking speed. 
Narrative review NA 
Gill D et al. 2011 Painful diabetic neuropathy, Post-herpetic 
neuralgia, Trigeminal neuralgia, Phantom 
limb pain, Postoperative or traumatic 
neuropathic pain, CRPS, Cancer-related 
neuropathy, Guillain Barré, HIV-neuropathy, 
Spinal cord injury, Fibromyalgia (UNCLEAR) 
3 Primary outcomes: Patient-reported pain relief of 30%-
50% or greater, PGIC much or very much improved. 
Secondary outcomes: Any pain-related outcome 
indicating some improvement, Withdrawals due to lack 
of efficacy, Participants experiencing any adverse event, 
Withdrawals due to adverse events, somnolence and 
dizziness. 
RR with 95% CI using 
fixed effect model 
≥30-50% 
Goodyear-Smith F 
& Halliwell J 2009 
Diabetic neuropathy, post herpetic neuralgia, 
trigeminal neuralgia, and post stroke pain 
(UNCLEAR) 
70 Pain relief (UNCLEAR) Narrative synthesis NA 
4 
 
Hauser W et al. 
2011 
Fibromyalgia and painful diabetic peripheral 
neuropathy (UNCLEAR)  
142 Rating of pain intensity- VAS, NRS, summary scores 
including non-painful symptoms (Paraesthesia and sleep 
numbness of feet). 
WMD and RR with 
95% CI using fixed 
effect model 
<10, 10-20 AND 
20-27 point 
change 
McQuay HJ et al. 
1996 
Diabetic neuropathy, post herpetic neuralgia, 
atypical facial pain and central pain (NA) 
17 Patient global judgement (excellent/good), Pain 
intensity (no pain/ slight pain or 50% decrease from 
‘neuropathy’ scale) or relief (good/ excellent), Improved 
or marked improvement and minor and major adverse 
effects. 
OR at 95% CIs in a 
fixed effect model 
>50% 
Moore RA et al. 
2009 
Chronic or neuropathic pain including 
diabetic neuropathy, post herpetic neuralgia 
(PHN), phantom limb pain, Guillain Barré, 
and spinal cord injury (PROBABLE NeP) 
19 Patient reported pain relief of 30%- 50% or greater, 
PGIC, Pain on movement, Pain at rest, Any other pain 
related measure, Adverse effects. 
RR with 95% CI using 
fixed effect model 
>30-50% 
Moore RA et al. 
2011 
Painful diabetic neuropathy, Post herpetic 
neuralgia, Trigeminal neuralgia, Phantom 
limb pain, Postoperative or traumatic 
neuropathic pain, CRPS, Cancer-related 
neuropathy, HIV-neuropathy, Spinal cord 
injury, Fibromyalgia (UNCLEAR) 
29 Primary outcomes: Patient reported pain intensity 
reduction of 30%- 50% or greater, PGIC much or very 
much improved, Secondary outcomes: Any pain-related 
outcome indicating some improvement, Withdrawals 
due to lack of efficacy, Participants experiencing any 
adverse event, Withdrawals due to adverse events, 
somnolence and dizziness. 
RR with 95% CI using 
fixed effect model 
30-50% 
Straube S et al. Post herpetic neuralgia, painful diabetic 21 At least 50% pain relief, PGIC: much or very much NNT, RR and RB with 50% 
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2008 neuropathy, fibromyalgia and neuropathic 
pain after spinal cord injury (NA) 
improved, Withdrawals due to lack of efficacy, 
Withdrawals due to adverse events, Somnolence and 
Dizziness. 
95% CIs using fixed 
effect model 
Straube S et al. 
2010 
Neuropathic pain and CRPS (POSSIBLE NeP) 1 Primary outcomes: Participants with   30% pain relief, or 
at least “much improved” in PGIC, Participants with   
50% pain relief, or “very much improved” in PGIC. 
Secondary outcomes: Participants with < 30% or “mild” 
pain relief, or undefined improvement, Pain relief 
lasting < 4 weeks, Adverse events and complications, 
Occurrence of persistent serious new or expanded pain. 
RR with 95% CI using 
fixed effect model 
<30%, ≥30%, 
≥50% 
Wiffen PJ et al. 
2011 
Acute, chronic or cancer pain (UNCLEAR) 15 Patient reported pain relief of 50% or greater, PGIC, 
Pain on movement, Pain on rest or spontaneous pain 
and any other pain related outcomes, Adverse events. 
NNT and RR with 95% 
CI using fixed effect 
model 
30-50% 
Entrapment Neuropathy 
Caliandro P et al. 
2011 
People with clinical symptoms suggesting the 
presence of UNE with or without 
neurophysiological evidence of entrapment 
(UNCLEAR)  
6 Primary outcomes: Improvement in function measured 
by Disability of the Arm, Shoulder and Hand 
questionnaire or the UNE questionnaire. 
Secondary outcomes: Change in neurological 
impairment, Change from baseline of the motor nerve 
MD, OR (random 
effect model) and RR 
with 95% CI using 
fixed effect model 
NA 
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conduction velocity across the elbow, Change from 
baseline in the nerve diameter, Change in quality of life 
and Adverse events. 
Herpes Zoster 
Cao H et al. 2010 Herpes zoster (UNCLEAR) 8 Reduction in severity of pain, Duration of relief of pain, 
Percentage of cured patients and Incidence rate of PHN. 
RR and MD with 95% 
CI using fixed effect 
model 
NA 
Neuropathic pain of any aetiology 
Ang CD et al. 2008 Generalized peripheral neuropathy (NA) 13 Primary outcomes: VAS and a neuropathy impairment 
score. 
Secondary outcomes: Long-term (after more than three 
months) change in pain intensity or impairment, Short-
term and long-term change in neuropathic symptoms, 
Short-term and long-term change in nerve conduction 
study parameters, Serious adverse events.  
RR with 95% CI using 
fixed effect model 
and MD with 95% CIs 
NA 
Eisenberg E et al. 
2005 
Central or peripheral neuropathic pain of any 
aetiology (NA)  
9 Differences in pain intensity, pain relief, and the 
incidence and severity of adverse effects. 
WMD with 95% CIs NA 
Eisenberg E et al. 
2006 
Peripheral neuropathic pain of any aetiology 
(NA)  
22 Pain intensity using a VAS; type and amount of opioid 
and control used; and incidence of adverse effects 
RR with 95% CI using 
fixed effect model 
NA 
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during treatment with opioid or control. and MD with 95% CIs 
Eisenberg E et al. 
2006 
Central or peripheral neuropathic pain of any 
aetiology (NA)  
23 Visual Analogue Scale. NNT with 95% CI 
using fixed effect 
model 
NA 
Hollinshead J et al. 
2006 
Peripheral neuropathy (NA)  7 Primary outcomes: The primary outcome measure was 
50% or more pain relief, or 50% or more reduction of 
the score on a validated pain scale. 
Secondary outcomes: 50% or more reduction in touch-
evoked pain after at least two weeks of treatment, 
Adverse events, which are life threatening, prolong or 
require hospitalisations, or lead to death. 
RR and  NNT with 95% 
CI using fixed effect 
model 
50% 
Lunn MP et al. 2009 Any form of painful peripheral neuropathy or 
chronic pain (UNCLEAR) 
6 Primary outcomes: VAS and categorical scales. 
Secondary outcomes: Long-term (more than 12 weeks) 
improvement of pain, Improvement in short-term and 
long-term pain of at least 30% compared with baseline, 
Improvement in any validated Quality of Life Score of 
more than 30% compared to the baseline, Adverse 
events during treatment. 
RR, NNT and WMD 
with 95% CI using 
fixed effect model  
30-50% 
Mason L et al. 2004 Chronic pain from neuropathic or 14 50% reduction in pain. This was the number of patients NNT, RR and RB with 50% 
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musculoskeletal disorders (NA)  with either a “good” or “excellent” global assessment of 
treatment or “none” or “slight” pain on rest or 
movement measured on a suitable categorical scale. 
95% CI using fixed 
effect model 
Moore RA & 
McQuary HJ 2005 
Arthritis/ musculoskeletal/ neuropathic pain/ 
Mixed (NA)  
34 Adverse event rates Adverse event rate 
with 95% CI  
NA 
Papaleontiou M et 
al. 2010 
Osteoarthritis, neuropathic pain, or other 
pain-producing disorders (UNCLEAR) 
43 Pain (UNSPECIFIED) and physical function outcomes by 
WOMAC, physical quality of life by SF-36 physical 
component, mental quality of life and sleep. 
NNT and RR with 95% 
CI using fixed effect 
model 
NA 
Pittler  MH & Ernst 
E 2008 
Neuropathic pain or neuralgic pain (NA) 15 Pain relief (UNSPECIFIED). NNT and RR with 95% 
CI using fixed effect 
model 
NA 
Plested M 2010 Refractory NeP (central or peripheral) 
(UNCLEAR) 
17 Pain relief (VAS), Overall quality of life (SF-MPQ total, 
sensory and affective scores and SF-12), function 
interference, sleep interference, interference of mood, 
daily activities and pain associated distress, safety, 
tolerability. 
Narrative synthesis NA 
Saarto T & Wiffen 
PJ 2007 
Any neuropathic pain (NA)  61 Measures of effectiveness: patient-reported global 
improvement or pain relief, or both. Overall quality of 
life measures, Adverse effects measures, sleep 
RR with 95% CI using 
fixed effect model 
NA 
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parameters, Depression scales. 
Seidel S et al. 2008 Acute, chronic or both pains (NA) 11 Primary outcomes: The reduction in pain intensity as 
measured by VAS, self-reported global scale, VRS, NRS 
or categorical pain relief scale, and self-reported pain 
relief. 
Secondary outcomes: adverse effects. 
Additional outcomes: Attrition, Measures of satisfaction 
or patient preference and assessment of quality of life. 
WMD and RR with 
95% CI using fixed 
effect model 
NA 
Tremont-Lukats IW 
et al. 2005 
Neuropathic pain of any aetiology (NA) 27 A change in the 0–100 mm VAS, Adverse events. WMD and OR in a 
random effect model 
NA 
White CM et al. 
2004 
Peripheral neuropathy, including sensory, 
motor and combined sensory and motor 
neuropathies (NA) 
3 Primary outcomes: Functional ability (walking, stair 
climbing and running), functional use of the affected 
arm/s and/or independence in activities of daily living 
such as washing, dressing, preparing food etc. 
Secondary outcomes: Muscle strength, Endurance, 
Psychological status or quality of life, Return to work, 
Relapse and use, or increased use, of analgesics. 
WMD and RR at 95% 
CIs in a random effect 
model 
NA 
10 
 
Wiffen PJ et al. 
2011 
Painful diabetic neuropathy, Post herpetic 
neuralgia, Trigeminal neuralgia, Phantom 
limb pain, Postoperative or traumatic 
neuropathic pain, CRPS, Cancer-related 
neuropathy, HIV-neuropathy, Spinal cord 
injury, fibromyalgia (UNCLEAR) 
17 Primary outcomes: Patient reported pain intensity 
reduction of 30%- 50% or greater, PGIC much or very 
much improved. 
Secondary outcomes: Any pain-related outcome 
indicating some improvement, Withdrawals due to lack 
of efficacy, Participants experiencing any adverse event, 
Withdrawals due to adverse events, somnolence and 
dizziness. 
NNT and RR with 95% 
CI using fixed effect 
model 
30-50% 
Painful HIV-associated sensory neuropathy 
Phillips TJC et al. 
2010 
Painful HIV-Associated Sensory Neuropathy 
(UNCLEAR)  
14 Pain improvement (UNCLEAR) NNT with 95% CIs ≥30%, ≥50% 
Post herpetic Neuralgia 
Alper BS & Lewis PR 
2002 
Post herpetic neuralgia (NA) 27 Pain resolution, VAS, Quality of life and adverse effects. Narrative synthesis 50% 
Hempenstall K et al. 
2005 
Post herpetic neuralgia (NA) 35 Patient related global scale for pain relief and VAS or 11 
point NRS for pain intensity. 
RB and NNT with 95% 
CI using fixed effect 
≥50% 
11 
 
model  
Khaliq W et al. 2007 Post herpetic neuralgia (NA) 12 Primary outcomes: Mean improvement in patients’ 
reports of pain relief measured by a categorical scale. 
Secondary outcome: Mean reduction in VAS scores, 
Highest recorded blood lidocaine level, The proportion 
of participants with one or more adverse skin reactions.  
RR, NNT and MD with 
95% CI using fixed 
effect model  
NA 
Volmink J et al. 
1996 
Post herpetic neuralgia (NA) 3 Pain relief by VAS and VRS. OR at 95%CIs in a 
random effect model 
NA 
Traumatic Spinal Cord Injury & Central NeP 
Denkers MR et al. 
2002 
Traumatic spinal cord injury and central 
neuropathic pain (NA) 
11 Rating of pain relief, Decreased usage of pain 
medication, Interference with daily activities. 
Narrative synthesis NA 
Trigeminal Neuralgia 
Chole R et al. 2007 Trigeminal neuralgia (NA)  21 Adverse effects. RB with 95% CI 
using fixed 
effect model 
NA 
12 
 
Liu H et al. 2010 Trigeminal neuralgia (UNCLEAR) 12 Cured rate (UNSPECIFIED), Adverse effects. OR with 95% 
CIs 
NA 
Lopez BC et al. 2004 Trigeminal neuralgia (NA) 31 Pain relief (UNSPECIFIED) and Complications. Narrative 
synthesis 
NA 
Yang M et al. 2011 Trigeminal Neuralgia, both idiopathic and 
symptomatic (UNCLEAR) 
4 Primary outcomes: Immediate improvement in pain 
relief evaluated as decreased pain intensity or TN scores 
i.e. number of attacks per day and their intensity. 
Secondary outcomes: Improvement in pain intensity or 
TN scores at least 12 weeks after the start of treatment 
and Adverse effects. 
MD and RR 
with 95% CI 
using fixed 
effect model 
NA 
Zakrzewska JJM & 
Linskey ME 2008 
Trigeminal neuralgia (NA)  11 Primary outcomes: Complete pain relief. 
Secondary outcomes: Surgical morbidity, Quality of life, 
Patient satisfaction and adverse events. 
RR and MD 
with 95% CI 
using fixed 
effect model 
NA 
CIs= Confidence intervals, MD= Mean difference, NA= Not Applicable, NNT= Number Needed to Treat, NRS= Numerical Rating Scale, OR= Odds Ratio, PGIC= Patient Global 
Impression of Change, RB= Relative Benefit Ratio, RR= Relative Risk Ratio, SF 36 / 12= The Medical Outcome Study Short Form Health Survey-36 / 12, SF-MPQ= Short Form-McGill 
Pain Questionnaire, SMD= Standardized mean difference, TN= Trigeminal Neuralgia, UNE= Ulnar Neuropathy at Elbow, VAS= Visual Analog Scale, VRS= Verbal Rating Scale, 
WOMAC= The Western Ontario and McMaster Universities Arthritis Index, WMD= Weighted mean difference  
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Table 3. Treede’s (2008) Grading system for the level of certainty for the presence of NeP 
No. Criteria to be evaluated for each patient 
1 Pain with a distinct neuroanatomically plausible distribution* 
2 A history suggestive of a relevant lesion or disease affecting the peripheral or central 
somatosensory system† 
3 Demonstration of the distinct neuroanatomically plausible distribution by at least 
one confirmatory test‡ 
4 Demonstration of the relevant lesion or disease by at least one confirmatory test§ 
Grading of definite NeP: all (1 to 4); probable NeP: 1 and 2, plus either 3 or 4; possible NeP: 1 and 2, 
without confirmatory evidence from 3 or 4. 
*A region corresponding to a peripheral innervation territory or to the topographic representation 
of a body part in the CNS. 
†The suspected lesion or disease is reported to be associated with pain, including a temporal 
relationship typical for the condition. 
‡As part of the neurologic examination, these tests confirm the presence of negative or positive 
neurologic signs concordant with the distribution of pain. Clinical sensory examination may be 
supplemented by laboratory and objective tests to uncover subclinical abnormalities. 
§As part of the neurologic examination, these tests confirm the diagnosis of the suspected lesion/ 
disease. These confirmatory tests depend on which lesion/ disease is causing NeP. 
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Table 4. Summary of reviews using ‘Physical Functional Outcome Measures’ as an outcome measure 
Reference  Treede’s NeP 
Grading 
Functional Outcome Measure Tools/ Scales No of 
RCT's 
Studies using 
FOM 
Ites KI et al. 2011 UNCLEAR Functional reach test 6 1 
Eccles NK 2005 NA 15m walking speed, pain disability index, functional 
status, physical functions, WOMAC, effects on function 
21 7 
Caliandro P et al. 2011 UNCLEAR Disability of the Arm, Shoulder and Hand questionnaire 6 6 
Papaleontiou M et al. 
2010 
UNCLEAR Pain disability index and SF-36: physical component  43 2 
Plested M 2010 UNCLEAR Daily activities measured by VRS and Function 
interference measured by NRS. 
17 2 
White CM et al. 2004 NA WOMAC: functional component, One and five time 3 3 
Table
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scored functional activity, Sub scale of SF-36, 6m 
comfortable walking speed or 6m gait speed. 
Denkers MR et al. 2002 NA Improvement in functional capacity.  11 1 
NA= Not Applicable, NRS= Numerical Rating Scale, SF-36= The Medical Outcome Study Short Form Health Survey-36, VRS= Verbal 
Rating Scale, WOMAC= The Western Ontario and McMaster Universities Arthritis Index 
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Table 5. PRISMA items and criteria (Liberati A 2009). √=YES ×=NO: 
 
Particulars 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
Total 
( √ ) 
1 Diabetic Neuropathy 
1.1 Chen W et al. 2011 × √ √ × √ √ √ √ √ √ √ × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 24 
1.2 Hurley RW et al. 2008 √ √ √ √ × √ √ √ √ √ √ × √ √ √ × √ √ × √ √ √ × √ × √ √ 21 
1.3 Ites KI et al. 2011 √ √ √ × × √ √ × √ × √ √ √ × × × √ √ √ √ × × × √ √ √ × 16 
1.4 Li H 2008 √ √ √ × × × √ √ √ √ √ √ √ √ √ × √ √ √ √ × √ × √ √ √ √ 21 
1.5 Wong MC et al. 2007 √ √ √ × × √ √ √ √ √ × √ √ √ × √ √ √ √ √ √ × √ √ × √ √ 21 
2 Diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, post stroke pain, Phantom limb pain, Fibromyalgia, CRPS and GB syndrome 
2.1 
Challapalli V et al. 
2005 
√ √ √ √ × √ √ × √ √ √ √ √ √ × √ √ √ √ √ √ √ √ √ × √ √ 23 
2.2 Collins SL et al. 2000 √ √ √ √ × √ √ × × × √ √ √ × × × √ √ × √ × × √ √ × √ √ 16 
2.3 Eccles NK 2005 × √ √ × × × √ × × × × √ × × × × × √ √ × × × × √ × √ √ 9 
2.4 Gill D et al. 2011 × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ √ × √ √ √ √ √ √ 24 
2.5 
Goodyear-Smith F & 
Halliwell J 2009 
× √ √ × × × √ √ × √ × √ × × × × √ × × × × × × √ √ √ √ 11 
2.6 Hauser W et al. 2011 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 27 
2.7 McQuay HJ et al. 1996 √ √ √ × × √ √ × √ × × √ √ × × × × √ √ √ × × √ √ × √ √ 15 
2.8 Moore RA et al. 2009 × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ √ √ × √ √ √ √ √ 24 
2.9 Moore RA et al. 2011 × √ √ × √ √ √ √ √ √ √ √ √ × × √ × √ √ √ √ √ √ √ √ √ √ 22 
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2.10 Straube S et al. 2008 √ √ √ √ × √ √ √ × × √ √ √ √ √ × × √ √ × √ × √ √ × √ √ 19 
2.11 Straube S et al. 2010 × √ √ √ √ √ √ √ √ √ √ × √ √ √ √ × √ √ √ × × × √ × √ √ 20 
2.12 Wiffen PJ et al. 2011 × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 26 
3 Entrapment Neuropathy 
3.1 Caliandro P et al. 2011 × √ √ × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 25 
4 Herpes Zoster 
4.1 Cao H et al. 2010 √ √ √ × × √ √ × √ √ × √ √ √ √ × √ √ √ √ √ √ × √ × √ √ 20 
5 Neuropathic pain of any aetiology 
5.1 Ang CD et al. 2008 × √ √ √ √ √ √ √ √ √ × √ √ √ √ √ × √ √ √ √ × √ √ × √ √ 22 
5.2 Eisenberg E et al. 2005 × √ √ × √ √ √ √ √ √ √ √ √ √ × × √ √ √ √ √ × × √ × √ √ 20 
5.3 Eisenberg E et al. 2006 √ √ √ √ × √ √ √ × √ × √ √ √ × √ √ √ × √ √ × √ √ × √ √ 20 
5.4 Eisenberg E et al. 2006 √ √ √ √ × √ √ × √ √ √ √ √ √ × × √ √ √ √ √ × √ √ √ √ √ 22 
5.5 
Hollingshead J et al. 
2006 
× √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ 25 
5.6 Lunn MP et al. 2009 × √ √ × √ × √ √ √ √ × √ √ √ √ √ √ √ √ √ √ × √ √ × √ √ 21 
5.7 Mason L et al. 2004 √ √ √ √ × √ √ √ × √ √ √ √ √ × × √ √ √ √ √ × × √ √ √ × 20 
5.8 
Moore RA & McQuary 
HJ 2005 
√ √ √ × × √ √ × × × √ √ × × × √ × √ × √ √ × √ √ × √ √ 15 
5.9 Papaleontiou M et al. √ √ √ √ × √ √ × √ √ √ √ √ √ √ √ √ √ × × √ √ √ √ √ √ √ 23 
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2010 
5.10 
Pittler MH & Ernst E 
2008 
√ √ × × × × √ × × × × × × × × × × × × × × × × × √ √ √ 6 
5.11 Plested M 2010 √ √ √ × × √ √ √ √ √ × √ × × × × √ √ × √ × × × √ √ √ √ 16 
5.12 
Saarto T & Wiffen PJ 
2007 
× √ √ × √ √ √ √ √ √ √ × √ √ × √ × √ √ √ √ × √ √ × √ √ 20 
5.13 Seidel S et al. 2008 × √ √ √ √ √ √ √ √ √ √ √ √ × × √ √ √ √ √ √ × √ √ √ √ √ 23 
5.14 
Tremont-Lukats IW et 
al. 2005 
× √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ √ √ √ √ √ √ √ √ 25 
5.15 White CM et al. 2004 × √ √ √ √ √ √ √ √ √ √ × √ √ × √ √ √ √ √ √ × √ √ √ √ √ 23 
5.16 Wiffen PJ et al. 2011 × √ √ × √ √ √ √ √ √ × √ √ × × × × √ √ √ √ × √ √ √ √ √ 19 
6 Painful HIV-associated sensory neuropathy 
6.1 Phillips TJC et al. 2010 √ √ √ × × × √ × √ √ √ √ √ √ × √ √ √ × √ √ × × √ × √ √ 18 
7 Post herpetic Neuralgia 
7.1 
Alper BS & Lewis PR 
2002 
√ √ √ × × √ √ √ × √ × √ × × × × √ √ √ √ × × × √ √ √ √ 16 
7.2 
Hempenstall K et al. 
2005 
√ √ √ × × √ √ × √ √ × √ √ √ × √ √ √ × √ √ × √ √ × √ √ 19 
7.3 Khaliq W et al. 2007 × √ √ √ √ √ √ √ √ √ √ × √ × √ √ √ √ √ √ √ √ × √ √ √ √ 23 
7.4 Volmink J et al. 1996 × √ √ × × √ × × × √ √ √ √ √ × × × √ √ √ √ × √ √ √ √ √ 17 
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8 Traumatic SCI & Central NeP 
8.1 
Denkers MR et al. 
2002 
√ √ √ √ × √ √ × √ √ √ × × × × × × √ × √ × × × √ √ √ √ 15 
9 Trigeminal Neuralgia 
9.1 Chole R et al. 2007 √ √ √ × × × √ √ × × × × × × × × √ √ × × × × × √ × √ × 9 
9.2 Liu H et al. 2010 √ √ √ × × × √ √ × × √ × × × × × × √ × × × × × √ × √ × 9 
9.3 Lopez BC et al. 2004 √ √ √ × × × √ × × √ √ √ √ × × × √ √ √ × × × × √ × √ √ 14 
9.4 Yang M et al. 2011 × √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ √ √ × × √ √ √ √ 23 
9.5 
Zakrzewska JJM & 
Linskey ME 2008 
× √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ × √ √ √ × × × √ × √ √ 21 
1. Title: Identify the report as a systematic review, meta-analysis, or both. 
2. Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration number. 
3. Rationale: Describe the rationale for the review in the context of what is already known. 
4. Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
5. Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and,  if available, provide registration information including registration number. 
6. Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow‐up) and report characteristics (e.g., years considered,  language, publication status) used as criteria for eligibility, giving rationale. 
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7. Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
8. Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 
9. Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and , if applicable, included in the meta‐analysis). 
10. Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
11. Data items:  List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 
12. Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is 
to be used in any data synthesis. 
13. Summary measures:  State the principal summary measures (e.g., risk ratio, difference in means).  
14. Synthesis of results:  Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta‐analysis. 
15. Risk of bias across studies:  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). 
16. Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre‐specified. 
17. Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
18. Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
19. Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 
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20. Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally 
with a forest plot. 
21. Synthesis of results:  Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
22. Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item 15). 
23. Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 
24. Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). 
25. Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). 
26. Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research. 
27. Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
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